

COVID-19 TOWN HALL

November 4th

Agenda

• COVID-19 State and National Updates

- COVID-19 Vaccines Update
 - Dr. Karen Lewis- Medical Director, Arizona Immunization Program Office-Arizona Department of Health Services
- Q&A




State and National Updates

Kelly Fine Executive Director | Arizona Pharmacy Association


Worldwide Cases

JOHNS HOPKINS




National Cases





Daily confirmed new cases (3 day moving average)




JOHNS HOPKINS CORON

CORONAVIRUS RESOURCE CENTER

Cases per US State (Deaths)				
950,302	Texas (18,632)			
	California (17,745)			
816,700	Florida (16,890)			
	New York (33,543)			
	Illinois (10,161)			
	Georgia (8,029)			
280,377	North Carolina (4,457)			
	Tennessee (3,454)			
	Arizona (6,020)			
	New Jersey (16,371)			
	Wisconsin (2,099)			
	Ohio (5,363)			
	Pennsylvania (8,842)			
	Michigan (7,761)			
	Alabama (2,987)			
	Missouri (3,043)			

ARIZONA DEPARTMENT OF HEALTH SERVICES Health and Wellness for All Arizonans


		Number of Cases	Number of Deaths	Number of COVID-19 Tests
Arizona-	Tweet G Share	249,818	6,020	2,124,628
Current R _t Cases Tests 1.12 248,137 1,792,573		Number of New Cases reported today*	Number of New Deaths reported today*	Number of New Tests reported today*
Effective Reproduction Rate · R _t		1,679	38	11,071
R _t is the average number of people who become infected by an infectious person. If it's above 1.0, COVID-19 will spread q 1.0, infections will slow. Learn More.	uickly. If it's below	Rate of cases, per 100,000 population	Rate of fatalities, per 100,000 population	Total Percent Positive**
²⁵ 9/2/20: 0.81 9/9/20: 0.92		3,475.0	83.74	9.6%
2.0 Shelter Ended 9/15/20: 1.01 .shelter Started Reopening 10/21/20: 1.10 1.5 10/28/20: 1.10		Total COVID-19 Diagnostic Tests***	New Diagnostic Tests reported today*	Diagnostic Tests Percent Positive**
	1.12	1,803,235	10,630	10.1%
1.0 3/1 3/8 3/15 3/22 3/29 4/5 4/12 4/19 4/26 5/3 5/10 5/17 5/24 5/31 6/7 6/14 6/21 6/28 7/5 7/12 7/19 7/26 8/2 8/9 8/16 8/23 8/30 9/6 9/13 9/20 9/27	10/40/110/180/25 11/1	Total COVID-19 Serology Tests	New Serology Tests reported today*	Serology Percent Positive**
שיון איז	10/410/11/0/10/0/25 11/1	321,393	441	6.5%



Laboratory Testing



Diagnostic tests completed for COVID-19	Diagnostic tests reported yesterday in Total Arizona	% Positive COVID-19 Diagnostic Tests	Date	Positive Diagnostic %
1,803,235	10,630	10.1%	6/17/20	8.7%
Select a county to filter the data. Hover over a county for more details. 20K 15K 15K 29,067 41,831 28,267242 10K 48,14 5,453 1062,276,085,39868 5K	Diagnostic tests by date of collection	Weekly PCR Positivity %	6/24/20	10.5%
	20К	6/28/20 = 21% 7/5/20 = 19%	7/1/20	12%
	LSK-	7/12/20 = 16% 7/19/20 = 12%	7/8/20	13.6
	юк	7/26/20 = 10%	7/15/20	14.2%
	56	8/2/20 = 8% 8/9/20: 6%	7/22/20	14.6%
	ok dibbati	8/23/20-10/4/20: 4%	7/29/20	14.6%
15,297	Apri Mayi Juni Juli Augi Sepi Octi Novi	10/11/20: 5% 10/18/20: 6%	8/5/20	14.4%
COVID-19 tests completed and percent positive by week 10/25/20: 8% 11/1/20: 9%				13.9%
Percent positive is defined as number of people with a positive test result, reported electronically out of all people with COVID-19 testing reported include PCR and antigen testing.			9/1/20	12.6%
Total % Positive COVID-19 Diagnostic Tests 10.1% Febr., Mar., Apri., Apri., May., May., June., July., July., Aug., Sept., Sept., Octo., Octo.,		9/8/20	12.2%	
		9/15/20	11.9%	
		10/20/20	10.4%	
	14.39	***********	10/27/20	10.2%
7.0%	M., A., A., A., A., M., M., M., M., Ju, Ju, Ju, Ju, Ju, Ju, Ju, Ju, Ju,		11/3/20	10/1%



HHS Partners with CVS and Walgreens to Provide COVID-19 Vaccine to Long-Term Care Facilities

- <u>HHS and DOD announced a CDC partnership</u> with CVS and Walgreens to provide vaccine services in nursing homes and assisted living once a COVID-19 vaccine has been approved and authorized.
- Facilities can partner with CVS, Walgreens, <u>or existing LTC pharmacy</u> and indicate what that is. The program is not limited to CVS and Walgreens.
- Facilities need to sign up between October 19th-November 6th and indicate their pharmacy preference through the <u>NHSN portal</u>. Assisted living facilities will indicate their pharmacy preference through an <u>online sign-up form</u>.
- <u>FAQ</u>

ROPA- (Referring, Ordering, Prescribing and Attending)

- The <u>Patient Protection and Affordable Care Act (ACA)</u> and the <u>21st Century</u> <u>Cures Act (Cures)</u> require that all health care providers who provide services to, order (refer), prescribe, or certify health care services for AHCCCS members must be enrolled as an AHCCCS provider.
- Until these Acts passed, referring, ordering, prescribing and attending providers were required to obtain a National Provider Identifiers (NPI's) but were not required to be enrolled as an AHCCCS provider.
- After Jan. 1, 2021 claims which include referring, ordering, prescribing or attending providers who are not enrolled with AHCCCS will not be reimbursed.

<u>CLICK HERE</u>

ROPA-Continued

- AHCCCS informed us that pharmacists do <u>NOT</u> have to register with AHCCCS as providers as we discussed on the call. They have created an exception process and are in the process of gathering immunization trained pharmacist's NPI's, State Board of Pharmacy license numbers, and necessary demographic information.
- If you work for Fry's, Safeway/Albertsons, Walgreens, CVS, Walmart, Bashas, or Costco: your company will be working directly with AHCCCS to provide this information on your behalf therefore you do <u>NOT</u> need to do anything.
- If you are an immunization trained pharmacist (or will be before January 1, 2021) that works for another pharmacy who plans to offer vaccines to AHCCCS members please fill out this survey and I will submit the information to AHCCCS to follow-up on.

CLICK HERE TO COMPLETE SURVEY

CMS <u>Issues Rule</u> Clarifying that All Public and Private Health Plans Must Cover Cost Sharing and Administration for FDA Approved or Authorized COVID-19 Vaccines

- Any FDA or EUA COVID-19 vaccine will be covered.
- The COVID-19 vaccine will be free for patients and providers. Providers will be paid an established fee for administration for Medicare patients, and a "reasonable" administration fee is suggested for Medicaid and commercial plans.
- If a patient is enrolled in a Medicare Advantage (MA) plan, the COVID-19 vaccine provider should bill Medicare Part B.
- Pharmacies providing COVID-19 vaccine to Medicare patients must be an enrolled Medicare provider or a mass immunizer with Medicare.
 - https://www.cms.gov/medicare/covid-19/enrollment

CDC updates- <u>Interim Guidance</u> for Routine and Influenza Immunization Services during the COVID-19 Pandemic

New guidelines recommend postponing all vaccination visits for the following individuals:

- Asymptomatic and pre-symptomatic persons who have tested positive: 10 days from a positive test result
- **Symptomatic persons**: Met criteria to discontinue isolation; 10 days after symptom onset and 24 hours with no fever without the use of fever-reducing medications, and COVID-19 symptoms improving; and no longer moderately to severely ill
- **Persons exposed to a person with COVID-19**: After 14-day quarantine period has ended


Added new section:

 Additional Considerations for Influenza Vaccination of Persons in Healthcare Facilities and Congregate Settings during the COVID-19 Pandemic

CDC COVID-19 Playbook 2.0

CDC has released an <u>updated playbook</u> for distribution of the COVID-19 vaccine which includes:

- Updated information on the federal pharmacy partnership for COVID-19 vaccination in long-term care (LTC) facilities and information on federal direct allocations to pharmacy partners in Phase 2 of vaccine distribution and administration.
- Direct allocation opportunities will be provided to retail chain pharmacies and networks of community pharmacies (minimum of 200 stores) and of independent pharmacies through PSAO's.



COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations

Centers for Disease Control and Prevention (CDC)

> October 29, 2020 Version 2.0



Overview of COVID-19 Vaccines

November 4, 2020


Presenting To
AzPA Town Hall | Phoenix AZ

Karen Lewis, M.D. | AIPO Medical Director



Coronaviruses

- Common colds (4)
- Severe Acute Respiratory Syndrome (SARS)
- Middle East Respiratory Syndrome (MERS)
- 2019 Novel Coronavirus






Operation Warp Speed for COVID-19 Vaccines



RESOURCES COLLABORATION APPROVAL



Vaccine Development






Vaccines in Phase 3 Clinical Trials

- Pfizer
- Moderna
- AstraZeneca (U of Oxford)
- Janssen




mRNA COVID-19 Vaccines





Pfizer diagram

mRNA Codes for Spike Protein






Pfizer diagram

Pfizer (mRNA)

- 2 doses scheduled
 <u>></u> 21 days apart
- Five doses in each MDV
- Shipped in trays of 195 vials (~1,000)
- Needs -70^o C for storage and handling
- 2º to 8º C for up to 5 days
- Dilution at point of use (use in 6 hours)



mRNA-1273 encodes for the full-length Spike Protein in the Pre-fusion Conformation (S-2P)



Miller, ACIP, August 26, 2020




moderna Slide 3

Moderna (mRNA)


- 2 doses scheduled > 28 days apart
- 10 doses in each MDV
- Shipped in boxes of 10 MDV (100 doses)
- Needs -20^o C for storage and handling
- 2º to 8º C for up to 14 days
- No dilution




Janssen COVID-19 Vaccine Non-replicating Recombinant Adenovirus



AstraZeneca COVID-19 Vaccine Non-replicating Viral Vector



COVID-19 Vaccine (Novavax) Spike Proteins + Adjuvant




Spike proteins

- Starting phase 3 soon
- Storage at 2º-8º C
- Two doses



Sanofi Pasteur COVID-19

- Recombinant spike protein with GSK adjuvant
 - Phase 1/2
 - Storage at 2-8º C
 - 2 doses





• Also developing a mRNA vaccine



Inovio COVID-19 Vaccine


- DNA plasmid
- Given with electroporation
- Phase 2
- Stable at room temperature for 1 year
- Two doses





Vaxart COVID-19 Vaccine


- Non-replicating human adenovirus 5 with adjuvant
- Tablet for oral administration
- Phase 1
- Stable at room temperature
- Two doses





Medicago COVID-19 Vaccine


- Viral-like particle with adjuvant
- Phase 1 trial
- Stable at 2-8° C
- Two doses





Merck Measles COVID-19 Vaccine Vector

- SARS-CoV-2 spike proteins expressed on measles virus surface
- Phase 1 trial
- 1-2 doses



 Merck is also developing a recombinant vesicular stomatitis virus COVID-19 vaccine




Current Vaccines with Related Platforms

- MMR (RNA)
- Varicella vaccine (DNA)
- Hepatitis B vaccine (Recombinant)
- HPV vaccine (VLP)
- Flublok (baculovirus vector)
- Fluad quadrivalent (adjuvant)



Rate Limiting Steps






Vaccine and Antiviral Prioritization Advisory Committee in 2020



Pandemic Vaccine Distribution



Provider Onboarding at ASIIS Home Page <u>https://asiis.azdhs.gov</u>



Health and Wellness for all Arizonans



Arizona Immunization Program Office

COVID-19 VACCINE

PROVIDER ONBOARDING CAMPAIGN

WE WANT TO BE PREPARED AND ENGAGE OUR PARTNERS NOW, SO WE ARE READY WHEN VACCINES ARE AVAILABLE FOR DISTRIBUTION IN ARIZONA.

BOTH VFC AND NON-VFC PROVIDERS WHO WOULD LIKE TO ADMINISTER FUTURE COVID-19 VACCINES MUST COMPLETE THE PANDEMIC PROVIDER ONBOARDING SURVEY FORMS.

> FOLLOW THE LINK BELOW TO ACCESS THE PANDEMIC VACCINE PROVIDER ONBOARDING SURVEY FORMS



Questions?